Eosinophilic granuloma is an unusual benign disease that usually affects the pediatric population and young adults. It is the most benign of the diseases traditionally known as histiocytosis X that are now called Langerhans cell histiocytosis. Pediatric patient with a painful lump in the temporal region. The imaging tests carried out reveal the existence of an osteolytic lesion with an aggressive pattern compatible with eosinophilic granuloma. The patient underwent surgery with a conclusive definitive histological diagnosis of eosinophilic granuloma. Eosinophilic granuloma can affect one or multiple bones, of which the most frequent are the cranial bones, epiphyses of long bones and ribs, requiring individualized diagnosis and treatment strategies for optimal management and results, with surgical treatment of First choice. Eosinophilic granuloma is an infrequent benign condition that requires a correct anamnesis and clinical examination of the patient, as well as the demonstration of the characteristic radiological images, allowing a generally accurate presumptive diagnosis to be reached that in most cases can be considered definitive. Eosinophilic granuloma is an infrequent benign condition that requires a correct anamnesis and clinical examination of the patient, as well as the demonstration of the characteristic radiological images, allowing a generally accurate presumptive diagnosis to be reached that in most cases can be considered definitive. The present work describes the clinical characteristics and interventions to minimize morbidity and mortality in hospitalized patients diagnosed with COVID-19. It is a prospective cohort investigation of patients who received a response from the Health Centers in the southeast region (RS) of the metropolitan area (AMBA) from April 8 to September 30, 2020. A Situation Room was used epidemiological with two monitoring and follow-up boards, one for bed management and the other for patient management. During the analyzed period, 2,588 patients with confirmed COVID-19 diagnosis were admitted, 1,943 with suspected COVID-19 pathology, and 1,464 subjects with other pathologies. 55% of the patients were men and the mean age was 51 years. There were 82.8% patients with pre-existing diseases, hypertension and diabetes were the most frequent. 14% were hospitalized in the Intensive Care Unit. The mortality of the cohort was 15.05%, mortality was higher for men, with a mean age of 60 years, 92.65% had some pre-existing disease. Our cohort is younger than other published works. Older people, men, and people with comorbidities are at increased risk for COVID-19-related mortality. The public health system was able to respond to the demand without collapsing the hospital institutions. Our cohort is younger than other published works. Older people, men, and people with comorbidities are at increased risk for COVID-19-related mortality. The public health system was able to respond to the demand without collapsing the hospital institutions. Coronavirus disease 2019 (COVID-19) is a public health problem worldwide. https://www.selleckchem.com/products/amg-232.html After 3 weeks of the onset of the disease, between 10-87% of patients persist with symptoms. The objective of the study was to evaluate the persistence of symptoms in patients with COVID-19, the associated factors, and to explore the patients' perception of the disease. We conducted a cross-sectional study that included 85 patients with a confirmed diagnosis of COVID-19, who attended on an outpatient basis after the acute phase (> 3 weeks) of the disease. The median time from diagnosis to outpatient consultation was 53 days (interquartile range 31-65). Most (86%) had mild disease, 45% were women and the mean age was 43 years (standard deviation of 13). After the acute phase of the disease 52% (95% CI 41-63%) of the patients persisted with symptoms. The most frequently persistent symptoms were fatigue (49%) and cough (33%). Nineteen percent had insomnia and sixteen percent had anxiety. Female sex, obesity, age between 35-55 years, and initial hospitalization were associated with the persistence of symptoms. Twenty percent of the patients stopped following the prevention recommendations because they believed they were immunized. More than half of the patients persisted with symptoms 3 weeks after the COVID-19 diagnosis, so medical follow-up is important. Female sex, obesity, age 35-55 years, and initial hospitalization were associated factors. The symptoms usually resolved over time. More than half of the patients persisted with symptoms 3 weeks after the COVID-19 diagnosis, so medical follow-up is important. Female sex, obesity, age 35-55 years, and initial hospitalization were associated factors. The symptoms usually resolved over time.Editorial.Transarterial chemoembolization (TACE) is a therapeutic option for patients with intermediate-stage hepatocellular carcinoma (HCC) or metastatic liver cancers. Identifying those patients who particularly benefit from TACE remains challenging. Macrophage migration inhibitory factor (MIF) represents is an inflammatory protein described in liver cancer patients, but no data on its prognostic relevance in TACE patients exist. Here, we evaluate MIF serum concentrations as a potential biomarker in patients undergoing TACE for primary and secondary hepatic malignancies. MIF serum concentrations were measured by multiplex immunoassay in n=50 patients (HCC n=39, liver metastases n=11) before and one day after TACE as well as in 51 healthy controls. Serum concentrations of MIF did not differ between patients and healthy controls. Interestingly, in the subgroup of patients with larger tumor size, significantly more patients had increased MIF concentrations. Patients with an objective tumor response to TACE therapy showed comparable concentrations of serum MIF compared to patients who did not respond. MIF concentrations at day 1 after TACE were significantly higher compared to baseline concentrations. Importantly, baseline MIF concentrations above the optimal cut-off value (0.625 ng/ml) turned out as a significant and independent prognostic marker for a reduced overall survival (OS) following TACE Patients with elevated MIF concentrations showed a significantly reduced median OS of only 719 days compared to patients below the cut-off value (median OS 1430 days, p = 0.021). Baseline MIF serum concentrations are associated with tumor size of intrahepatic malignancies and predict outcome of liver cancer patients receiving TACE.